In the ongoing search for novel immunotherapies that might rival or surpass the efficacy of immune checkpoint inhibitors, drugs targeting IDO1—a key enzyme in tryptophan metabolism—have been a major focus in recent years.
James P. Stevenson, MD, discusses available biomarker-driven therapies in non–small cell lung cancer, as well as rarer biomarkers under clinical investigation.
R. Steven Paulson, MD, discusses how to adapt to the era of precision medicine, the latest with liquid biopsies, and a unique diagnostic tool with the potential to revolutionize oncology.
Sreeni Chittoor, MD, FACP, discusses the role of liquid biopsies in non–small cell lung cancer and the advantages of using this type of assay compared with tissue-based genotyping across cancer types.
Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.
Faculty from Texas Oncology and Quest Med Fusion highlight exciting ongoing research efforts at their respective institutions.
Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.
Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.
Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.
Miguel A. Villalona-Calero, MD, discusses the availability of ALK inhibitors for patients with ALK-positive non–small cell lung cancer and the importance of implementing sequencing panels to guide treatment.